Home › Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline
 

Keywords :   


Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline

2014-02-05 07:22:08| drugdiscoveryonline News Articles

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, recently announced its key “Alnylam 5x15” pipeline goals. The company also announced today that it now expects to exceed its original “Alnylam 5x15” guidance from 2011, where Alnylam had guided to have five genetic medicine programs in the clinic by the end of 2015

Tags: key goals pipeline therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
21.09Strategies to minimize fallback pigs in the nursery
21.09This Week in Agribusiness, Sept. 21, 2024
21.09This Week in Agribusiness, Sept. 21, 2024
21.09RABapp provides rapid response insight in animal health emergencies
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
More »